Adicet provides corporate update and highlights strategic priorities for 2024

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024. “in 2024, we aim to make significant strides across our pipeline of differentiated gamma delta t cell therapies through our strategic and disciplined approach,” said chen s.
ACET Ratings Summary
ACET Quant Ranking